Cholinergic agonists have previously been shown to augment the ability of sensitized lymphocytes to injure cells bearing the sensitizing alleantigens. The cholinergic receptor of the attacking lymphocyte population has been studied with pharmacological manipulation of an in vitro system that quantitates the injury mediated Iby sensitized attacking cells upon target cells.
cholinergic receptor of the attacking lymphocyte population has been studied with pharmacological manipulation of an in vitro system that quantitates the injury mediated Iby sensitized attacking cells upon target cells.
The data reveal that muscarinic ligands are several orders of magnitude more potent than nicotinic agents in altering cytotoxicity.
Mice transplanted with histoincompatible grafts develop thymus-derived (T) lymphocytes which are selectively cytotoxic in vitro for cells bearing donor transplantation antigens (lymphocyte-mediated cytotoxicity or LMC) (1, 2) . In a similar in vitro system, rats have been demonstrated to develop cytotoxic lymphocytes post-transplantation (3) . Since the cytotoxic rat lymphoid cells do not adhere to glass bead columns (unpublished observation) or bear easily detectable surface immunoglobulin (4), it seems reasonable to assume that the effector cell is also a T lymphocyte. A variety of metabolic inhibitors (5) (6) (7) (8) (9) (10) and increased intracellular levels of adenosine 3':5'-cyclic monophosphate (cyclic AMP) (3, 4, 11, 12) inhibit the ability of sensitized T cells to injure appropriate histoincompatible target cells; however, cholinergic agonists (3, 4) and 8-bromo guanosine 3':5'-cyclic monophosphate (8-bromo cyclic GMP) (4) have been found to enhance cytotoxicity. Since cholinergic stimulation of a variety of tissues (13) (14) (15) (16) (17) (18) (19) , including lymphocytes, (18, 19) results in increased intracellular levels of cyclic GMP, these data indicate that the intracellular concentration of cyclic GMP, Acting as a classical second messenger, is important in determining the extent of cytotoxicity, as is the level of cyclic AMP. The effect of cyclic GMP upon cytotoxicity has been shown to be upon the attacking lymphocyte population at the moment of initial attacking and target cell interaction (4) .
Cholinergic receptors, classically designated muscarinic and nicotinic, have been differentiated by the use of agents which stimulate or block these receptors. It was previously shown that cholinergic augmentation of LMC was blocked by atropine (3) . Although atropine is considered a muscarinic antagonist, several studies indicate that atropine can interact with nicotinic receptors (20-25), i.e., those found on skeletal muscle (20) (21) (22) (23) (24) and sympathetic neurons (25) . In this study, the cholinergic receptor of the attacking lymphocyte (cytotoxic T lymphocytes) population has been studied using pharmacologic manipulation of LMC. The results reveal that both muscarinic and nicotinic antagonists inhibit cholinergic augmentation of LMC; however, muscarinic ligands are two-to three orders of magnitude thore potent.
MATERIALS AND METHODS
Carbamylcholine chloride, atropine sulfate, d-tubocurarine chloride, and hexamethonium bromide were purchased from Sigma Chemical Co., St. Louis, Mo.; tetramethylammonium chloride was purchased from Aldrich Chemical Co., Milwaukee, Wisc.; RPMI-1640 medium and fetal-calf serum were purchased from Grand Island Biological Co.; Grand Island, N.Y. a-Bungarotoxin (a-BGT) was purified and tested for biologic activity as described previously (23 (27) , can augment LMC (3, 4) ; this effect is completely dependent upon a short period of preincubation of the attacking cells with the cholinergic agonist (4). The effect of muscarinic and nicotinic receptor antagonists upon carbamylcholine-induced augmentation of cytotoxicity was tested using four different cholinergic antagonists. In all experiments equimolar concentrations of atropine, a muscarinic antagonist (28) concentration (1.0 pM) had no effect; however, in much higher concentrations (1-10 /AM), atropine mimicked the effect of carbamylcholine in augmenting LMC.
d-Tubocurarine, a competitive blocking agent of nicotinic receptors at the myoneural junction and sympathetic ganglion (29) , did not block the enhancement of LMC by carbamylcholine at equimolar concentrations; however, in three experiments, this agent did cause dose-dependent inhibition of carbamylcholine-induced augmentation of LMC at concentrations of 0.1-50 nM (Table 2) . a-Bungarotoxin, a purified neurotoxin obtained from the venom of Bungarus multicinctus, binds to myoneural junction nicotinic receptors (30), (10) (11) (12) (13) (14) (15) (16) (17) The numbers listed in parenthesis are the range of triplicate samples c, ft, and u are as indicated in Table 1 . In three additional experiments, 50-100 nM a-bungarotoxin completely prevented the augmentation of LMC induced by 0.1-0.01 nM carbamylcholine (32%, 36%, and 41% to 0%, 1%, and 1%, respectively) and 1 nM a-bungarotoxin inhibited cholinergic enhancement of LMC (from 32%, 36%, and 41% to 14%, 17%, and 18%, respectively).
acetylcholine receptors of brain (31), sympathetic neurons (25) and electroplax (32) . a-Bungarotoxin was also ineffective in inhibiting the action of carbamylcholine at equimolar concentrations (Table 3) ; however, a 10-fold excess of abungarotoxin inhibited the enhancement of LMC produced by carbamylcholine and a 500-fold excess completely prevented cholinergic augmentation of cytotoxicity. Hexamethonium, an antagonist of nicotinic ganglionic receptors (33) , was without effect at all concentrations tested (Table 4) .
Tetramethylammonium (TMA), a predominantly nicotinic agonist (34) , caused concentration and time dependent enhancement of LMC (Fig. 1) . The augmentation of LMC produced by TMA is completely dependent upon a short period of preincubation of the attacking cells with this nicotinic agonist. Augmentation was not noted if the attacking cells were preincubated for more than 5 min prior to the introduction of the target cells, nor if the agonist was added at time of introduction of the target cells, or subsequent to the The numbers listed in parenthesis are the range of triplicate samples. Hexamethonium was found to be ineffective in antagonizing the action of carbamylcholine in three additional experiments.
Immunology: Strom et al. mixing of attacking and target cells. These findings are identical to the previously reported time-course studies with carbamylcholine (4), although a higher concentration of TMA than that of carbamylcholine is required for enhanced cytotoxicity.
DISCUSSION
Several lines of evidence indicate that T lymphocytes bear cholinergic receptors; cholinomimetic agents enhance LMC through an effect upon cytotoxic T lymphocytes (4) ; cholinergic agonists increase the release of migration inhibition factor from sensitized lymphocytes (19) ; cholinergic agonists increase lymphocyte proliferation noted in splenocytes explanted from animals undergoing the graft-versus-host reaction (35) and following phytohemagglutinin stimulation (19 (27) . Hexamethonium, an inhibitor of nicotinic ganglionic receptors (33) did not, however, abrogate cytotoxicity (Table 4) . Furthermore, TMA, a nicotinic agonist (34) (Fig. 1 (36) has been retained for 60 years (27) . Several studies have demonstrated, however, that the muscarinic antagonist, atropine, in large doses inhibits stimulation of neuromuscular receptors (20-25). The iontophoretic stimulation of rat diaphragm (21) and cultured muscle cells (22) with acetylcholine has been blocked by atropine concentrations 2000 and 100 times, respectively, in excess of the inhibitory concentrations of d-tubocurarine; furthermore, atropine may bind to neuromuscular (23, 24) and ganglionic (25) receptors with sufficient avidity to competitively inhibit the binding of nicotinic antagonists when the concentration of atropine exceeds that of the nicotinic ligands by several orders of magnitude. Functional inhibition of "muscarinic" systems by a-bungarotoxin or nicotinic antagonists has not been previously reported, to our knowledge. The data reported herein reveal that muscarinic ligands are several orders of magnitude more potent than nicotinic agents in altering LMC. These data and the work of other investigators indicate that differences between receptors designated muscarinic and nicotinic (20-25) are not absolute, but may reflect the relative concentration-dependent efficiency of various ligands to stimulate or inhibit a given cholinergic receptor.
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